117 related articles for article (PubMed ID: 31229949)
1. Novel phase I trial design to evaluate the addition of cediranib or selumetinib to preoperative chemoradiotherapy for locally advanced rectal cancer: the DREAMtherapy trial.
Marti FEM; Jayson GC; Manoharan P; O'Connor J; Renehan AG; Backen AC; Mistry H; Ortega F; Li K; Simpson KL; Allen J; Connell J; Underhill S; Misra V; Williams KJ; Stratford I; Jackson A; Dive C; Saunders MP
Eur J Cancer; 2019 Aug; 117():48-59. PubMed ID: 31229949
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
Hubbard JM; Yin J; Schenk EL; Qin R; Reid JM; Strand C; Fiskum J; Menefee M; Lin G; Doyle LA; Ivy P; Erlichman C; Adjei A; Haluska P; Costello BA
Invest New Drugs; 2022 Feb; 40(1):115-123. PubMed ID: 34515877
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
[TBL] [Abstract][Full Text] [Related]
4. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Takahashi O; Komaki R; Smith PD; Jürgensmeier JM; Ryan A; Bekele BN; Wistuba II; Jacoby JJ; Korshunova MV; Biernacka A; Erez B; Hosho K; Herbst RS; O'Reilly MS
Clin Cancer Res; 2012 Mar; 18(6):1641-54. PubMed ID: 22275507
[TBL] [Abstract][Full Text] [Related]
5. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Hofheinz RD; Wenz F; Post S; Matzdorff A; Laechelt S; Hartmann JT; Müller L; Link H; Moehler M; Kettner E; Fritz E; Hieber U; Lindemann HW; Grunewald M; Kremers S; Constantin C; Hipp M; Hartung G; Gencer D; Kienle P; Burkholder I; Hochhaus A
Lancet Oncol; 2012 Jun; 13(6):579-88. PubMed ID: 22503032
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.
Kim R; Prithviraj GK; Shridhar R; Hoffe SE; Jiang K; Zhao X; Chen DT; Almhanna K; Strosberg J; Campos T; Shibata D
Radiother Oncol; 2016 Feb; 118(2):382-6. PubMed ID: 26861740
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant accelerated concomitant boost radiotherapy and multidrug chemotherapy in locally advanced rectal cancer: a dose-escalation study.
Caravatta L; Picardi V; Tambaro R; Padula GD; Macchia G; Deodato F; Massaccesi M; Pacelli F; Berardi S; Ridolfini MP; Di Filippo L; Fabrizio G; Ingrosso M; Cellini N; Valentini V; Morganti AG
Am J Clin Oncol; 2012 Oct; 35(5):424-31. PubMed ID: 21555930
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
9. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.
Das P; Eng C; Rodriguez-Bigas MA; Chang GJ; Skibber JM; You YN; Maru DM; Munsell MF; Clemons MV; Kopetz SE; Garrett CR; Shureiqi I; Delclos ME; Krishnan S; Crane CH
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):301-5. PubMed ID: 24315563
[TBL] [Abstract][Full Text] [Related]
10. Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.
Goffin JR; Nicholas G; Mates M; Tu D; Chen E; Laurie SA; Juergens R; Robinson A; Goss G; Reaume M; Sun S; Christink K; Maize C; MacFarlan S; Sun X; Ritter H; Seymour L; Bradbury PA
Invest New Drugs; 2019 Jun; 37(3):498-506. PubMed ID: 30317534
[TBL] [Abstract][Full Text] [Related]
11. High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
Vestermark LW; Jensen HA; Pfeiffer P
Acta Oncol; 2012 Mar; 51(3):311-7. PubMed ID: 22248062
[TBL] [Abstract][Full Text] [Related]
12. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
Kim SY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Lee KS; Yun T; Jeong SY; Choi HS; Lim SB; Chang HJ; Jung KH
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):677-83. PubMed ID: 20888703
[TBL] [Abstract][Full Text] [Related]
13. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Kim SY; Shim EK; Yeo HY; Baek JY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Jung KH; Chang HJ
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):201-7. PubMed ID: 22672749
[TBL] [Abstract][Full Text] [Related]
15. Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).
Gollins SW; Myint S; Susnerwala S; Haylock B; Wise M; Topham C; Samuel L; Swindell R; Morris J; Mason L; Levine E
Br J Cancer; 2009 Sep; 101(6):924-34. PubMed ID: 19690550
[TBL] [Abstract][Full Text] [Related]
16. A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial).
Ishihara S; Matsusaka S; Kondo K; Horie H; Uehara K; Oguchi M; Murofushi K; Ueno M; Mizunuma N; Shinbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Nakajima T; Watanabe T
Radiat Oncol; 2015 Jan; 10():24. PubMed ID: 25612635
[TBL] [Abstract][Full Text] [Related]
17. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.
Dellas K; Höhler T; Reese T; Würschmidt F; Engel E; Rödel C; Wagner W; Richter M; Arnold D; Dunst J
Radiat Oncol; 2013 Apr; 8():90. PubMed ID: 23587311
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer.
Michael M; Chander S; McKendrick J; MacKay JR; Steel M; Hicks R; Heriot A; Leong T; Cooray P; Jefford M; Zalcberg J; Bressel M; McClure B; Ngan SY
Br J Cancer; 2014 Nov; 111(10):1924-31. PubMed ID: 25211659
[TBL] [Abstract][Full Text] [Related]
20. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.
Kennecke H; Berry S; Wong R; Zhou C; Tankel K; Easaw J; Rao S; Post J; Hay J
Eur J Cancer; 2012 Jan; 48(1):37-45. PubMed ID: 21664123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
